Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.46 |
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | BAX | Q07812 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9578601 | 0.86 | ESR2 (0.42) | ESR2ESR1MEN1KMT2AKDM4E | |
| SCHEMBL7563950 | 0.85 | ESR2 (0.41) | ESR2ESR1MEN1KMT2AKDM4E | |
| SCHEMBL1237150 | 0.83 | ESR2 (0.39) | ESR2ESR1MEN1KMT2AKDM4E | |
| SCHEMBL8616470 | 0.83 | ESR2 (0.39) | ESR2ESR1MEN1KMT2AKDM4E | |
| SCHEMBL8612601 | 0.83 | ESR2 (0.39) | ESR2ESR1MEN1KMT2AKDM4E | |
| SCHEMBL8616566 | 0.83 | ESR2 (0.39) | ESR2ESR1MEN1KMT2AKDM4E | |
| SCHEMBL8614487 | 0.83 | ESR2 (0.39) | ESR2ESR1MEN1KMT2AKDM4E | |
| SCHEMBL8616433 | 0.83 | ESR2 (0.39) | ESR2ESR1MEN1KMT2AKDM4E | |
| SCHEMBL8613624 | 0.83 | ESR2 (0.39) | ESR2ESR1MEN1KMT2AKDM4E | |
| SCHEMBL8416038 | 0.83 | ESR2 (0.39) | ESR2ESR1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8129412-B2 | Hydantoin derivatives useful as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-1828166-B1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1828166-A1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-0255236-B1 | Fluorine-containing chiral smectic liquid crystals | MINNESOTA MINING & MFG (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0360521-B1 | Achiral fluorine-containing liquid crystals | MINNESOTA MINING & MFG (US) | 1993-11-24 | — | — | EP | disclosed |
| US-5254747-A | Fluorine-containing chiral smectic liquid crystals | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| US-5196140-A | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-03-23 | — | — | US | disclosed |
| US-5082587-A | ACHIRAL FLUORINE-CONTAINING LIQUID CRYSTALS | 3M INNOVATIVE PROPERTIES COMPANY | 1992-01-21 | — | — | US | disclosed |
| EP-0360521-A2 | Achiral fluorine-containing liquid crystals | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-03-28 | — | — | EP | disclosed |
| US-4886619-A | TILTED OR LATENT TILTED MESOPHASES; BLENDS; FERROELECTRIC DEVICE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0313604-A1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT. | MERCK PATENT GMBH (DE) | 1989-05-03 | — | — | EP | disclosed |
| WO-1988008441-A1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1988-11-03 | — | — | WO | disclosed |
| EP-0255236-A2 | Fluorine-containing chiral smectic liquid crystals | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ESR2 338/4885ESR1 1871/4885MEN1 4525/4885 |
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | MMP3, MMP9, MMP2 | ESR2 2397/4885ESR1 3770/4885MEN1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.